Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.

Carcinoma, Non-Small-Cell Lung / drug therapy Humans Lung Lung Neoplasms / drug therapy
Early-stage lung cancer Locally advanced lung cancer Non–small cell lung cancer Radiation toxicity Small cell lung cancer Stereotactic body radiation therapy

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
08 2022
Historique:
received: 18 01 2022
revised: 10 05 2022
accepted: 12 05 2022
pubmed: 2 6 2022
medline: 10 8 2022
entrez: 1 6 2022
Statut: ppublish

Résumé

Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.

Identifiants

DOI: 10.1016/j.jtho.2022.05.003 PMID: 35649502
pubmed: 35649502
pii: S1556-0864(22)00261-1
doi: 10.1016/j.jtho.2022.05.003
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

961-973

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.

Auteurs

Nicholas W Bucknell (NW)

Department of Radiation Oncology, Sir Charles Gardiner Hospital, Perth, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: nicholas.bucknell@health.wa.gov.au.

José Belderbos (J)

Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

David A Palma (DA)

Department of Oncology, Western University, London, Ontario Canada.

Puneeth Iyengar (P)

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas.

Pamela Samson (P)

Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.

Kevin Chua (K)

Division of Radiation Oncology, National Cancer Centre, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Programme, Duke-National University of Singapore (NUS) Medical School, Singapore.

Daniel Gomez (D)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Fiona McDonald (F)

Department of Radiotherapy, The Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom.

Alexander V Louie (AV)

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Corinne Faivre-Finn (C)

Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Gerard G Hanna (GG)

Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, United Kingdom.

Shankar Siva (S)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Avoiding Toxicity With Lung Radiation Therapy:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Avoiding Toxicity With Lung Radiation Therapy:...
questionsmedicales.fr › Appareil respiratoire › Poumon › Avoiding Toxicity With Lung Radiation Therapy:...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Avoiding Toxicity With Lung Radiation Therapy:...